Citius pharmaceuticals, inc. reports fiscal second quarter 2023 financial results and provides business update

$29.1 million in cash and cash equivalents as of march 31, 2023; $15 million registered direct offering in may 2023 extends runway through may 2024 halo-lido phase 2b trial completed with topline results anticipated by end of calendar q2 2023 cranford, n.j. , may 12, 2023 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal second quarter ended march 31, 2023.
CTXR Ratings Summary
CTXR Quant Ranking